Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices – such as rebate walls – would likely lead to legal action being taken against PBMs.
FTC Goes After PBMs, Warns Of Legal Action
